Iqbal Jabed, Liu Ting, Mapow Beth, Swami Vanlila K, Hou J Steve
Department of Pathology, Singapore General Hospital, Singapore.
Anal Quant Cytol Histol. 2010 Jun;32(3):161-5.
To determine the criteria for the use of immunophenotyping by flow cytometry (FCM) in the diagnosis of hematopoietic lesions.
A retrospective review of 89 consecutive body fluid specimens with concurrent FCM analysis during 2001 to 2006 was performed. The cytopathologic diagnosis was compared with the final diagnosis as modified by subsequent FCM.
The cytopathologic diagnosis was benign in 61 cases (69%), atypical in 20 cases (22%) and malignant in 8 cases (9%). In patients without any prior clinical history, FCM study was positive in 2 cases and negative in 49 cases. In these patients, the working cytopathologic diagnosis was modified from benign/atypical to malignant in 2 (11%) cases and atypical to benign in 11 (33%) cases. In patients with a prior clinical history, FCM was positive in 23 cases and negative in 15 cases.
FCM studies were helpful in the cytopathologic diagnosis in 35% of body fluid specimens, permitting appropriate cancer staging and management. In the absence of a prior clinical history, immunophenotyping by FCM in body fluid specimens should be ordered after adequacy studies when there is cytologic atypia or a strong suspicion of malignancy on the cytopathologic diagnosis.
确定流式细胞术（FCM）免疫表型分析在造血系统病变诊断中的应用标准。
对2001年至2006年间连续89例同时进行FCM分析的体液标本进行回顾性研究。将细胞病理学诊断与后续FCM修正后的最终诊断进行比较。
细胞病理学诊断为良性61例（69%），非典型20例（22%），恶性8例（9%）。在无任何既往临床病史的患者中，FCM研究阳性2例，阴性49例。在这些患者中，细胞病理学初步诊断从良性/非典型修正为恶性2例（11%），从非典型修正为良性11例（33%）。在有既往临床病史的患者中，FCM阳性23例，阴性15例。
FCM研究对35%的体液标本的细胞病理学诊断有帮助，有助于进行适当的癌症分期和治疗。在无既往临床病史的情况下，当体液标本细胞病理学诊断存在细胞学非典型或高度怀疑恶性时，在充分评估后应进行FCM免疫表型分析。
